The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis
Open accessAbstract
BACKGROUND: Readmission rates following hospitalisation for COPD exacerbations are unacceptably high, and the contributing factors are poorly understood. Our objective was to summarise and evaluate the factors associated with 30- and 90-day all-cause readmission following hospitalisation for an exacerbation of COPD. METHODS: We systematically searched electronic databases from inception to 5 November 2019. Data were extracted by two independent authors in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Study quality was assessed using a modified version of the Newcastle-Ottawa Scale. We synthesised a narrative from eligible studies and conducted a meta-analysis where this was possible using a random-effects model. RESULTS: In total, 3533 abstracts were screened and 208 full-text manuscripts were reviewed. A total of 32 papers met the inclusion criteria, and 14 studies were included in the meta-analysis. The readmission rate ranged from 8.8-26.0% at 30 days and from 17.5-39.0% at 90 days. Our narrative synthesis showed that comorbidities, previous exacerbations and hospitalisations, and increased length of initial hospital stay were the major risk factors for readmission at 30 and 90 days. Pooled adjusted odds ratios (95% confidence intervals) revealed that heart failure (1.29 (1.22-1.37)), renal failure (1.26 (1.19-1.33)), depression (1.19 (1.05-1.34)) and alcohol use (1.11 (1.07-1.16)) were all associated with an increased risk of 30-day all-cause readmission, whereas being female was a protective factor (0.91 (0.88-0.94)). CONCLUSIONS: Comorbidities, previous exacerbations and hospitalisation, and increased length of stay were significant risk factors for 30- and 90-day all-cause readmission after an index hospitalisation with an exacerbation of COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the 90-day readmission rate estimated for the UAE (35.9%) falls in the upper range of the published readmission rates [16,23].”
From Chronic Obstructive Pulmonary Disease in the Gulf Cooperation Council: Acute-Care Utilization and Medication Adherence: A PRISMA-ScR Scoping Review (2026) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“These findings are consistent with the international COPD literature demonstrating that multimorbidity and greater disease severity are associated with an increased risk of hospital readmission following COPD exacerbation [23].”
From Chronic Obstructive Pulmonary Disease in the Gulf Cooperation Council: Acute-Care Utilization and Medication Adherence: A PRISMA-ScR Scoping Review (2026) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“In other studies, the rate of 30-day readmissions was between 8.8% and 26.0%, whereas the rate of 90-day readmissions was between 17.5% and 39.0% [23].”
From Chronic Obstructive Pulmonary Disease in the Gulf Cooperation Council: Acute-Care Utilization and Medication Adherence: A PRISMA-ScR Scoping Review (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
(2014) · Medical Entomology and Zoology · Cited by 17,633
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,806
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A. R., Locantore, N., Müllerová, H., Tal‐Singer, R., Miller, B. E., Lomas, D. A., Agustí, A. G. N., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,983
Donaldson, G. C. (2002) · Thorax · doi:10.1136/thorax.57.10.847 · Cited by 2,268
Garcia-Aymerich, J., Lange, P., Benet, M., Schnohr, P., & Anto, J. M. (2006) · Thorax · doi:10.1136/thx.2006.060145 · Cited by 1,113
Miravitlles, M. (2004) · Thorax · doi:10.1136/thx.2003.008730 · Cited by 563
Cheung, P. T., Wiler, J. L., Lowe, R. A., & Ginde, A. A. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.01.035 · Cited by 315
Greening, N. J., Williams, J. E., Hussain, S., Harvey‐Dunstan, T. C., Bankart, M. J., Chaplin, E., Vincent, E. E., Chimera, R., Morgan, M. D., Singh, S. J., et al. (2014) · BMJ · doi:10.1136/bmj.g4315 · Cited by 289
Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit
Hartl, S., López-Campos, J. L., Pozo-Rodrı́guez, F., Castro-Acosta, A. A., Studnicka, M., Kaiser, B., & Roberts, C. M. (2015) · European Respiratory Journal · doi:10.1183/13993003.01391-2014 · Cited by 243
Understanding Why Patients With COPD Get Readmitted
Shah, T., Churpek, M. M., Perraillon, M. C., & Konetzka, R. T. (2014) · CHEST Journal · doi:10.1378/chest.14-2181 · Cited by 214 · cited 8×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialKristensen, S. R., Bech, M., & Quentin, W. (2014) · Health Policy · doi:10.1016/j.healthpol.2014.12.009 · Cited by 184
Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions
Couillard, S., Larivée, P., Courteau, J., & Vanasse, A. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.003 · Cited by 175 · cited 1×
“2017 (10) Univariate analysis: • Eosinophil counts ≥200 cells/mL or ≥2% vs <200, OR 1.”
BackgroundBahadori, K., & FitzGerald, J. M. (2007) · PubMed Central · Cited by 162
Nguyen, H. Q., Chu, L., Liu, I.-L. A., Lee, J. S., Suh, D., Korotzer, B., Yuen, G., Desai, S. A., Coleman, K. J., Xiang, A. H., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201401-017oc · Cited by 147 · cited 7×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialAssociation of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD
Singh, G. K., Zhang, W., Kuo, Y., & Sharma, G. (2015) · CHEST Journal · doi:10.1378/chest.15-0449 · Cited by 147 · cited 8×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialShort- and Medium-term Prognosis in Patients Hospitalized for COPD Exacerbation
Almagro, P., Soriano, J. B., Cabrera, F. J., Boixeda, R., Ortiz, M. B. A., Barreiro, B., Díez‐Manglano, J., Murio, C., & Heredia, J. L. (2013) · CHEST Journal · doi:10.1378/chest.13-1328 · Cited by 143
Sharif, R., Parekh, T. M., Pierson, K. S., Kuo, Y., & Sharma, G. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201310-358oc · Cited by 135 · cited 9×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialLoh, C. H., Peters, S. P., Lovings, T. M., & Ohar, J. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201611-903oc · Cited by 131 · cited 2×
“Seven papers looked at risk factors for 90-day readmission (1, 2, 6, 19, 20, 25, 32).”
BackgroundJacobs, D. M., Noyes, K., Zhao, J., Gibson, W., Murphy, T. F., Sethi, S., & Ochs‐Balcom, H. M. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201712-913oc · Cited by 119 · cited 9×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
InfluentialPenalizing Hospitals for Chronic Obstructive Pulmonary Disease Readmissions
Feemster, L. C., & Au, D. H. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1541pp · Cited by 117
Prediction models for exacerbations in patients with COPD
Guerra, B., Gaveikaite, V., Bianchi, C., & Puhan, M. A. (2017) · European Respiratory Review · doi:10.1183/16000617.0061-2016 · Cited by 113
Press, V. G., Au, D. H., Bourbeau, J., Dransfield, M. T., Gershon, A. S., Krishnan, J. A., Mularski, R. A., Sciurba, F. C., Sullivan, J. B., & Feemster, L. C. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201811-755ws · Cited by 105
Kon, S. S. C., Jones, S. E., Schofield, S. J., BANYA, W. A. S., Dickson, M. J., Canavan, J. L., Nolan, C. M., Haselden, B. M., Polkey, M. I., Cullinan, P., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207046 · Cited by 103 · cited 10×
“failure, renal failure and liver disease (1, 2, 6, 19, 32) (supplementary Table S3).”
BackgroundInfluentialRisk assessment of readmissions following an initial COPD-related hospitalization
Su, Baker, C. L., & Zou, K. H. (2013) · International Journal of COPD · doi:10.2147/copd.s51507 · Cited by 96 · cited 7×
“failure, renal failure and liver disease (1, 2, 6, 19, 32) (supplementary Table S3).”
BackgroundInfluentialTabak, C., Smit, H. A., Räsänen, L., Fidanza, F., Menotti, A., Nissinen, A. M., Feskens, E. J. M., Heederik, D. J. J., & Kromhout, D. (2001) · Epidemiology · doi:10.1097/00001648-200103000-00018 · Cited by 91
Echevarria, C., Steer, J., Heslop-Marshall, K., Stenton, S., Hickey, P. M., Hughes, R. J., Wijesinghe, M., Harrison, R. N., Steen, N. D., Simpson, A. J., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209298 · Cited by 84 · cited 8×
“failure, renal failure and liver disease (1, 2, 6, 19, 32) (supplementary Table S3).”
BackgroundInfluentialHakim, M. A., Garden, F. L., Jennings, M. D., & Dobler, C. C. (2017) · Clinical Epidemiology · doi:10.2147/clep.s149574 · Cited by 70 · cited 3×
“Previous exacerbations and hospitalisations 13 (1-3, 8, 14-16, 19, 21, 22, 25, 27, 32) 1 (3)”
BackgroundChawla, H., Bulathsinghala, C. P., Tejada, J. P., Wakefield, D. B., & ZuWallack, R. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201405-198oc · Cited by 60 · cited 4×
“Previous exacerbations and hospitalisations 13 (1-3, 8, 14-16, 19, 21, 22, 25, 27, 32) 1 (3)”
InfluentialEpstein, D., Nasser, R., Mashiach, T., Azzam, Z. S., & Berger, G. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.01.011 · Cited by 60 · cited 5×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
InfluentialGenao, L., Durheim, M. T., Mi, X., Todd, J. L., Whitson, H. E., & Curtis, L. H. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201504-250oc · Cited by 58 · cited 6×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
InfluentialChan, F. W., Wong, F. Y., Yam, C. H., Cheung, W.-L., Wong, E. L., Leung, M. C. M., Goggins, W. B., & Yeoh, E. (2011) · BMC Health Services Research · doi:10.1186/1472-6963-11-186 · Cited by 54 · cited 4×
“Sex 11 (3, 5, 7, 13-15, 18, 26-29) 8 (4, 6, 11, 17, 21, 22, 25, 31)”
InfluentialTrends in 30-day readmission rates after COPD hospitalization, 2006–2012
Goto, T., Faridi, M. K., Gibo, K., Toh, S., Hanania, N. A., Camargo, C. A., & Hasegawa, K. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.058 · Cited by 50
Identifying Patients With COPD at High Risk of Readmission
Simmering, J. E., Polgreen, L. A., Comellas, A. P., Cavanaugh, J. E., & Polgreen, P. M. (2016) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.3.4.2016.0136 · Cited by 49
Spece, L. J., Epler, E. M., Donovan, L. M., Griffith, M. F., Collins, M. P., Feemster, L. C., & Au, D. H. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201804-255oc · Cited by 49 · cited 2×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundGershon, A. S., Thiruchelvam, D., Aaron, S. D., Stanbrook, M. B., Vozoris, N. T., Tan, W. C., Cho, E., & To, T. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216741 · Cited by 47
Yu, T., Zhou, H., Suh, K., & Arcona, S. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s74181 · Cited by 44
Bollu, V. K., Ernst, F. R., Karafilidis, J., Rajagopalan, K., Robinson, S. B., & Braman, S. S. (2013) · International Journal of COPD · doi:10.2147/copd.s52557 · Cited by 34 · cited 5×
“Sex 11 (3, 5, 7, 13-15, 18, 26-29) 8 (4, 6, 11, 17, 21, 22, 25, 31)”
MethodInfluentialAssociation between length of stay and readmission for COPD.
Rinne, S. T., Graves, M. C., Bastian, L. A., Lindenauer, P. K., Wong, E. S., Hebert, P. L., & Liu, C. (2017) · PubMed · Cited by 34
Ehsani, H., Mohler, M. J., Golden, T. R., & Toosizadeh, N. (2018) · International Journal of COPD · doi:10.2147/copd.s182802 · Cited by 34 · cited 1×
“2019 (12) Multivariable analysis: • Frailty score was significantly associated with all-cause 30-day readmission in multi-variable analysis (F-ratio 6.”
BackgroundFunctional status at discharge and 30-day readmission risk in COPD
Nguyen, H. Q., Rondinelli, J. L., Harrington, A., Desai, S. A., Liu, I.-L. A., Lee, J. S., & Gould, M. K. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.12.004 · Cited by 33 · cited 8×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialRoberts, M. H., Mapel, D. W., Worley, A. V., & Beene, J. (2015) · Drugs in Context · doi:10.7573/dic.212278 · Cited by 28 · cited 7×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
BackgroundInfluentialPseudomonas aeruginosa infection increases the readmission rate of COPD patients
Choi, J., Oh, J. Y., Lee, Y. S., Hur, G. Y., Lee, S. Y., Shim, J. J., Kang, K. H., & Min, K. H. (2018) · International Journal of COPD · doi:10.2147/copd.s173759 · Cited by 26
Chronic Obstructive Pulmonary Disease Readmissions and Other Measures of Hospital Quality
Rinne, S. T., Castaneda, J., Lindenauer, P. K., Cleary, P. D., Paz, H. L., & Gómez, J. L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1944oc · Cited by 25
Bottle, A., Honeyford, K., Chowdhury, F., Bell, D., & Aylin, P. P. (2018) · Health Services and Delivery Research · doi:10.3310/hsdr06260 · Cited by 25 · cited 7×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
InfluentialEvaluation of prediction strategy and care coordination for COPD readmissions
Bashir, B., Schneider, D., Naglak, M. C., Churilla, T. M., & Adelsberger, M. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1210472 · Cited by 22
Rinne, S. T., Elwy, A. R., Bastian, L. A., Wong, E. S., Wiener, R. S., & Liu, C. (2017) · Medical Care · doi:10.1097/mlr.0000000000000708 · Cited by 22 · cited 2×
“Type of insurance 4 (14, 18, 26, 28) 6 (14, 17, 21-23, 28)”
BackgroundFactors associated with inpatient readmission among managed care enrollees with COPD
Candrilli, S. D., Dhamane, A. D., Meyers, J., & Kaila, S. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1085797 · Cited by 19 · cited 9×
“failure, renal failure and liver disease (1, 2, 6, 19, 32) (supplementary Table S3).”
BackgroundInfluentialAndreas, S., Röver, C., Heinz, J., Straube, S., Watz, H., & Friede, T. (2019) · Respiratory Research · doi:10.1186/s12931-019-1163-2 · Cited by 14
Hijjawi, S. B., Minshar, M. A., & Sharma, G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1015394 · Cited by 10 · cited 7×
“Comorbidities 22 (1-3, 5, 6, 8, 11, 13-15, 17-19, 21, 22, 26-32) 11 (6, 7, 15-18, 21, 22, 25, 27, 28)”
InfluentialReducing COPD readmissions—a personal and political priority
Medicine, T. L. R. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70153-x · Cited by 9
Hospital readmissions for COPD in England are rising, audit shows
Iacobucci, G. (2017) · BMJ · doi:10.1136/bmj.j557 · Cited by 7
COPD exacerbations: transforming outcomes through research
Hurst, J. R., Bafadhel, M., Bolton, C. E., Quint, J. K., Sapey, E., & Wilkinson, T. M. A. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30049-3 · Cited by 4
Cited by
Sorted by citations
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A. G. N., Celli, B. R., Criner, G. J., Halpin, D. M. G., Anzueto, A., Barnes, P. J., Bourbeau, J., Han, M. K., Martínez, F. J., de, M. M., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00239-2023 · Cited by 1,467
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A. G. N., Celli, B. R., Criner, G. J., Halpin, D. M. G., Anzueto, A., Barnes, P. J., Bourbeau, J., Han, M. K., Martínez, F. J., de, M. M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0106pp · Cited by 920
“A systematic review has shown that comorbidities, previous exacerbations and hospitalizations, and increased length of stay were signi fi cant risk factors for 30-and 90-day all-cause readmission after a hospitalized COPD exacerbation (151).”
Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis
Alqahtani, J. S., Oyelade, T., Aldhahir, A. M., Mendes, R. G., Alghamdi, S. M., Miravitlles, M., Mandal, S., & Hurst, J. R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255659 · Cited by 327
Adeloye, D., Elneima, O., Daines, L., Poinasamy, K., Quint, J. K., Walker, S., Brightling, C. E., Siddiqui, S., Hurst, J. R., Chalmers, J. D., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00286-1 · Cited by 126
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A. G. N., Celli, B. R., Criner, G. J., Halpin, D. M. G., Anzueto, A., Barnes, P. J., Bourbeau, J., Han, M. K., Martínez, F. J., de, M. M., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.02.009 · Cited by 135
Metadata
- Authors
- Alqahtani, J. S., Njoku, C. M., Bereznicki, B., Wimmer, B. C., Peterson, G. M., Kinsman, L., Aldabayan, Y. S., Alrajeh, A. M., Aldhahir, A. M., Mandal, S., & Hurst, J. R.
- Affiliations
- Prince Sultan Military College of Health Sciences (SA)
- University of Tasmania (AU)
- University of Newcastle Australia (AU)
- University College London (GB)
- Royal Free London NHS Foundation Trust (GB)
- Corresponding author
- Alqahtani, Jaber S.
- ORCID
- Venue
- European Respiratory Review
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-06-03
- Volume
- 29
- Issue
- 156
- Pages
- 190166
- ISSN
- 0905-9180 (ISSN-L)
- 1600-0617
- PMC
- PMC9488450
- OpenAlex
- W3033975634
- Cited by
- 149
- References
- 57
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 16 · 2023: 34 · 2022: 26 · 2021: 28 · 2020: 7
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- European Respiratory Review (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UTAS Research Repository (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- NOVA (University of Newcastle Australia) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- COPD exacerbations, hospital readmission, all-cause readmission, risk factors, comorbidities, heart failure, renal failure, depression, alcohol consumption, length of hospital stay, sex differences
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Middle Aged, Patient Readmission, Prognosis, Risk Factors, Time Factors, Comorbidity, Disease Progression, Risk Assessment, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
